Veeva Systems Inc. $VEEV Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp decreased its position in shares of Veeva Systems Inc. (NYSE:VEEV) by 73.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 246,477 shares of the technology company’s stock after selling 677,674 shares during the period. Van ECK Associates Corp owned 0.15% of Veeva Systems worth $73,428,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. GPS Wealth Strategies Group LLC boosted its position in shares of Veeva Systems by 196.4% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 83 shares of the technology company’s stock valued at $25,000 after purchasing an additional 55 shares during the period. Raiffeisen Bank International AG purchased a new stake in shares of Veeva Systems in the 3rd quarter valued at approximately $28,000. OLD Second National Bank of Aurora purchased a new stake in shares of Veeva Systems in the 3rd quarter valued at approximately $30,000. Cary Street Partners Investment Advisory LLC boosted its stake in Veeva Systems by 58.3% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 133 shares of the technology company’s stock worth $38,000 after purchasing an additional 49 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Veeva Systems during the second quarter valued at $41,000. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Veeva Systems Stock Performance

Shares of VEEV stock opened at $189.83 on Wednesday. The company has a market capitalization of $31.21 billion, a price-to-earnings ratio of 35.09, a PEG ratio of 1.35 and a beta of 1.09. The stock’s 50 day simple moving average is $202.20 and its 200 day simple moving average is $245.59. Veeva Systems Inc. has a twelve month low of $168.13 and a twelve month high of $310.50.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings data on Wednesday, March 4th. The technology company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $835.95 million during the quarter, compared to analysts’ expectations of $810.95 million. Veeva Systems had a net margin of 28.44% and a return on equity of 14.11%. Veeva Systems’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.74 earnings per share. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. On average, analysts forecast that Veeva Systems Inc. will post 4.35 EPS for the current fiscal year.

Veeva Systems announced that its board has initiated a share buyback plan on Monday, January 5th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the technology company to reacquire up to 5.5% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

More Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva announced the acquisition of Ostro, an AI‑driven brand engagement/chat platform for life sciences — a strategic bolt‑on to improve patient/physician engagement and add AI chat capabilities that can be cross‑sold into Veeva’s Commercial and Data Clouds; deal reported at ~$100M, signaling targeted M&A to accelerate growth. Veeva Systems Acquires Ostro for $100M
• Positive Sentiment: AOP Health is standardizing on the Veeva Industry Cloud across R&D, quality, commercial, and data — a notable customer win that supports recurring revenue and platform stickiness as Veeva ties development, quality and commercialization workflows for an international rare‑disease specialist. AOP Health Standardizes on Veeva Industry Cloud for Life Sciences Across All Business Areas
• Neutral Sentiment: Analysts and commentators note Veeva’s broader market positioning (including potential to support index/ETF performance), but these narratives are longer‑term and less likely to move the stock intraday compared with corporate actions and analyst revisions. Veeva Systems Success Could Support Russell 1000 ETF Performance Ahead
• Neutral Sentiment: Technical backdrop is unfavorable: price is below the 50‑day ($202.20) and 200‑day ($245.59) moving averages, which can exacerbate downside pressure while investors digest news and analyst revisions.
• Negative Sentiment: Citigroup lowered its VEEV price target from $319 to $291 while retaining a Buy rating — a material cut to upside expectations that can sap near‑term sentiment despite the firm still seeing significant upside vs. the current share price. Citigroup Has Lowered Expectations for Veeva Systems (NYSE:VEEV) Stock Price

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Barclays dropped their target price on Veeva Systems from $305.00 to $250.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Piper Sandler decreased their target price on shares of Veeva Systems from $355.00 to $285.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. William Blair reiterated an “outperform” rating on shares of Veeva Systems in a report on Tuesday. BTIG Research reissued a “buy” rating and issued a $340.00 price target on shares of Veeva Systems in a research note on Friday, November 21st. Finally, JPMorgan Chase & Co. dropped their price objective on Veeva Systems from $330.00 to $296.00 and set an “overweight” rating on the stock in a report on Friday, February 20th. Seventeen research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $283.70.

Insider Transactions at Veeva Systems

In other news, insider Thomas D. Schwenger sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $231.43, for a total value of $231,430.00. Following the sale, the insider directly owned 23,204 shares of the company’s stock, valued at approximately $5,370,101.72. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.30% of the stock is owned by company insiders.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.